trending Market Intelligence /marketintelligence/en/news-insights/trending/Xc0Dj9AlKHlEaPFYW0CV1g2 content esgSubNav
In This List

Eloxx Pharmaceuticals completes merger with Sevion Therapeutics

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Eloxx Pharmaceuticals completes merger with Sevion Therapeutics

Eloxx Pharmaceuticals Ltd. completed its reverse merger with Sevion Therapeutics Inc., effective Dec. 19.

The merged entity will be named Eloxx Pharmaceuticals Inc. and began trading on the OTCQB market Dec. 20.

All of the issued and outstanding ordinary and preferred shares of Eloxx stock were converted, on a pro rata basis, into the right to receive 20,316,656 Sevion common shares after giving effect to Sevion's reverse stock split.

After the reverse stock split and the acquisition, the combined company has about 27.6 million shares outstanding.